Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T J Lorenz

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
The Western Journal of Medicine|January 1, 1985
Acromegaly with 'normal' growth hormone levelsK R Feingold, T J Lorenz
Clinical Therapeutics|March 25, 1999
Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIaT J Lorenz, F Macdonald, M M Kitt
European Heart Journal|October 18, 2001
ESPRIT in context: pharmacology matters!J E Tcheng, J Strony, T J Lorenz, et al.
The Annals of Thoracic Surgery|October 4, 2000
Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin TherapyC M Dyke, D Bhatia, T J Lorenz, et al.
JAMA|May 23, 2001
Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trialJ C O'Shea, G E Hafley, S Greenberg, et al.
American Heart Journal|December 2, 2000
Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary interventionJ C O'shea, M Madan, W J Cantor, et al.
Journal of Diabetes and Its Complications|October 1, 1993
Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type I diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project TeamJ S Skyler, T J Lorenz, S Schwartz, et al.
Arthritis and Rheumatism|May 1, 1993
Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators GroupV Strand, P E Lipsky, G W Cannon, et al.
The Journal of Infectious Diseases|July 1, 1995
Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing proteinM A von der Möhlen, A N Kimmings, N I Wedel, et al.
Circulation|July 27, 2001
Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary interventionI C Gilchrist, J C O'Shea, T Kosoglou, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The Western Journal of Medicine|January 1, 1985
Acromegaly with 'normal' growth hormone levelsK R Feingold, T J Lorenz
Clinical Therapeutics|March 25, 1999
Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIaT J Lorenz, F Macdonald, M M Kitt
European Heart Journal|October 18, 2001
ESPRIT in context: pharmacology matters!J E Tcheng, J Strony, T J Lorenz, et al.
The Annals of Thoracic Surgery|October 4, 2000
Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin TherapyC M Dyke, D Bhatia, T J Lorenz, et al.
JAMA|May 23, 2001
Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trialJ C O'Shea, G E Hafley, S Greenberg, et al.
American Heart Journal|December 2, 2000
Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary interventionJ C O'shea, M Madan, W J Cantor, et al.
Journal of Diabetes and Its Complications|October 1, 1993
Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type I diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project TeamJ S Skyler, T J Lorenz, S Schwartz, et al.
Arthritis and Rheumatism|May 1, 1993
Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators GroupV Strand, P E Lipsky, G W Cannon, et al.
The Journal of Infectious Diseases|July 1, 1995
Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing proteinM A von der Möhlen, A N Kimmings, N I Wedel, et al.
Circulation|July 27, 2001
Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary interventionI C Gilchrist, J C O'Shea, T Kosoglou, et al.
Pageof 2